Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Issue Guidance for Setting Acceptable Limit for Nitrosamines This Fall
August 6, 2024
- MHLW to Streamline Deliberations on JP Revisions to Facilitate Use of Overseas APIs
August 6, 2024
- Humira Gets Health Coverage for nr-axSpA
August 6, 2024
- Takeda’s Fruzaqla in Line for Approval, Broader Labels for Truvada, Keytruda, Prevenar 20 Too
August 5, 2024
- Off-Year Debate Would Explore Ways to Address Drug Loss, Supply Issues with Drug Prices: Vice Minister
August 2, 2024
- Lilly’s Alzheimer’s Med Donanemab Now in Line for Japan Approval
August 2, 2024
- Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
- Japan OKs FY2025 Budget Ceiling, 410 Billion Yen for Social Security Cost Rise
July 31, 2024
- MHLW Council Begins Discussions on Rx-to-OTC Switch of 3 New APIs
July 31, 2024
- MHLW Panel Discusses Ways to Rationalize Ethical Narcotics Distribution
July 30, 2024
- Japan Panel Backs Rx-to-OTC Switch of 4 PPIs
July 30, 2024
- MHLW Mulls System to Seek Expert Input for Patent Linkage
July 29, 2024
- LDP Members Fret over Easier Access to Abortion Pill Mefeego
July 29, 2024
- Off-Year Revision Debate to Follow Honebuto Policy: MHLW Bureau Chief
July 29, 2024
- MHLW Plans Disposal of COVID-19 Antibody Meds in Government Stock
July 26, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
- Health Minister Hopes to Tap US Insights to Foster Japan Ecosystem
July 24, 2024
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…